EUVIMEDEUVIMED entdecken
Crossref

Diaryl terephthalamides as small-molecule disruptors of the c-Myb–CBP/p300 KIX protein–protein interaction: Mechanistic insights and biochemical validation

Haifa E Alfassam, Emadeldin M Kamel, Sarah I Othman, Hanan M Alharbi, Ahmed A Allam, Hassan A Rudayni, Al Mokhtar Lamsabhi

Biochemical and Biophysical Research Communications · 2026

DOI: 10.1016/j.bbrc.2026.154265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Haifa E Alfassam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, P.O. BOX 84428, Riyadh, 11671, Saudi Arabia. Electronic addre…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-myb, Phthalic Acids, E1A-Associated p300 Protein, p300-CBP Transcription Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Princess Nourah bint Abdulrahman University Deanship of Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The interaction between the transcription factor c-Myb and the CBP/p300 KIX domain is a functionally important protein-protein interface that supports oncogenic transcriptional programs in acute myeloid leukemia and therefore represents an attractive target for inhibitor discovery. Herein, we investigated diaryl terephthalamides as a new small-molecule chemotype for disruption of the c-Myb-CBP/p300 KIX interaction by integrating computational screening with experimental validation. A virtual-screening workflow was applied to a library diaryl terephthalamide derivatives affording five hit compounds (C1-C5). Docking and simulation results showed that C1 and C4 most consistently occupied the c-Myb-facing groove, whereas C5 adopted a distinct but still stable KIX-associated binding mode. Protein-protein interaction metrics calculations indicated that all five compounds weakened the c-Myb-KIX interface to varying extents, with C4 showing the strongest predicted disruptive effect and the most favorable ligand binding free energy, while C5 also exhibited substantial activity. MM/PBSA-based protein-protein interaction perturbation analysis further showed that all five compounds produced positive ΔΔGPPI values, consistent with weakening of the c-Myb-CBP/p300 KIX interface, with C4 and C5 showing the largest predicted disruptive effects (+25.85 and + 18.27 kcal/mol, respectively). Free-energy landscape analysis further supported stable low-energy binding states for C1 and C4, whereas C3 showed greater conformational heterogeneity. In silico ADMET profiling suggested that the series satisfies basic drug-likeness criteria but still carries notable developability liabilities requiring future optimization. Experimental microscale thermophoresis confirmed direct disruption of the Myb-KIX interaction, with C4 and C5 showing the best inhibitory potency, yielding IC50 values of 27.72 ± 7.80 and 27.11 ± 7.45 μM, respectively, compared with 34.74 ± 12.93 μM for Naphthol AS-E phosphate. Consistent with these biochemical findings, C4 and C5 showed the strongest reduction in AML cell viability in HL-60 and THP-1 cells. Overall, these findings identify diaryl terephthalamides as promising c-Myb-CBP/p300 KIX disruptors and establish C4 and C5 as the most compelling leads for further medicinal-chemistry development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mybPhthalic AcidsE1A-Associated p300 Proteinp300-CBP Transcription FactorsCREB-Binding ProteinSmall Molecule LibrariesHumansProtein BindingMolecular Docking Simulation

Stichwörter der Autor:innen

CBP/p300 KIXDiaryl terephthalamidesMicroscale thermophoresisProtein–protein interaction disruptorsc-Myb

Substanzen

Proto-Oncogene Proteins c-mybPhthalic AcidsE1A-Associated p300 ProteinEP300 protein, humanMYB protein, humanp300-CBP Transcription FactorsCREB-Binding ProteinSmall Molecule Libraries

Autor:innen und Institutionen

  • Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, P.O. BOX 84428, Riyadh, 11671, Saudi Arabia. Electronic address: halfassam@pnu.edu.sa.
  • Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, 62514, Egypt. Electronic address: emad.abdehameed@science.bsu.edu.eg.
  • Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, P.O. BOX 84428, Riyadh, 11671, Saudi Arabia.
  • Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 11623, Saudi Arabia.
  • Departamento de Química and Institute for Advanced Research in Chemical Science (IAdChem), Facultad de Ciencias, Módulo 13, Universidad Autónoma de Madrid, Madrid, 28049, Spain.

Förderung

  • Princess Nourah bint Abdulrahman University Deanship of Scientific Research

Zitieren

APA

Alfassam, H. E., Kamel, E. M., Othman, S. I., Alharbi, H. M., Allam, A. A., Rudayni, H. A., & Lamsabhi, A. M. (2026). Diaryl terephthalamides as small-molecule disruptors of the c-Myb–CBP/p300 KIX protein–protein interaction: Mechanistic insights and biochemical validation. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2026.154265

Vancouver

Alfassam HE, Kamel EM, Othman SI, Alharbi HM, Allam AA, Rudayni HA, et al. Diaryl terephthalamides as small-molecule disruptors of the c-Myb–CBP/p300 KIX protein–protein interaction: Mechanistic insights and biochemical validation. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2026.154265

BibTeX
@article{Alfassam2026,
  author = {Alfassam, Haifa E and Kamel, Emadeldin M and Othman, Sarah I and Alharbi, Hanan M and Allam, Ahmed A and Rudayni, Hassan A and Lamsabhi, Al Mokhtar},
  title = {Diaryl terephthalamides as small-molecule disruptors of the c-Myb–CBP/p300 KIX protein–protein interaction: Mechanistic insights and biochemical validation},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2026},
  doi = {10.1016/j.bbrc.2026.154265}
}
Kostenlos starten →